Table 5.
Exploratory analyses of BCFI rates by time to surgery after diagnosis according to patient characteristics and tumor subtype, The Ruijin cohort.
| Characteristics | ≤ 1week | 1–2 weeks | > 2 weeks | P value |
|---|---|---|---|---|
| Reference | HR (95% CI) | HR (95% CI) | ||
| Age | ||||
| < 40 | 1 | 1.97 (0.75–5.18) | 3.22 (1.12–9.33)* | 0.057 |
| 40–49 | 1 | 0.66 (0.21–2.13) | 1.61 (0.50–5.18) | 0.554 |
| 50–70 | 1 | 0.72 (0.27–1.95) | 1.47 (0.60–3.58) | 0.562 |
| > 70 | 1 | 0.30 (1.10–7.67) | 1.27 (0.30–5.37) | 0.096 |
| Pinteraction | 0.875 | |||
| Molecular subtype | ||||
| HR + /HER2− | 1 | 0.86 (0.38–1.95) | 1.35 (0.60–3.08) | 0.711 |
| HER2 + | 1 | 1.43 (0.62–3.31) | 3.66 (1.47–9.12)* | 0.017 |
| TNBC | 1 | 1.82 (0.72–4.58) | 1.42 (0.44–4.58) | 0.399 |
| Pinteraction | < 0.001 | |||
| Tumor stage | ||||
| Stage I | 1 | 2.45 (0.96–6.28) | 2.88 (1.05–9.38)* | 0.040 |
| Stage II | 1 | 0.95 (0.44–2.03) | 1.91 (0.97–3.76) | 0.170 |
| Stage III | 1 | 1.13 (0.46–2.81) | 0.97 (0.24–3.97) | 0.963 |
| Pinteraction | < 0.001 | |||
| Radiation therapy | ||||
| No | 1 | 1.73 (0.87–3.45) | 2.51 (1.21–5.19)* | 0.019 |
| Yes | 1 | 0.93 (0.45–1.89) | 1.30 (0.57–2.94) | 0.799 |
| Pinteraction | 0.003 | |||
*p < 0.05 compared with ≤ 1week group.